Ranibizumab Plus Fufang Xueshuantong Capsule Versus Ranibizumab Alone for Exudative Age-related Macular Degeneration

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2020 Sep 23

PMID 32962487

Citations 6

Authors

Hai-Tao Pan

Jun-Jun Wang

Jun-Long Huang

Yuan-Lu Shuai

Jia Li

Zi-Zhong Hu

Yu-Zhi Ding

Qing-Huai Liu

Affiliations

Soon will be listed here.

Abstract

Objective: To compare the efficacy of ranibizumab plus fufang xueshuantong capsule (cFXST) with the efficacy of ranibizumab alone in treatment of exudative age-related macular degeneration.

Methods: This prospective, randomized, controlled, pilot study included 38 eyes from 38 patients with exudative age-related macular degeneration (AMD) that were randomly allocated into two cohorts of 19 eyes each: ranibizumab (C) and ranibizumab plus cFXST (C). All patients received three monthly injections of ranibizumab. Patients in C also received daily oral supplementation of cFXST. Best corrected visual acuity (BCVA) and thickness of the choroidal neovascularization-pigment epithelial detachment (CNV-PED) complex (measured by optical coherence tomography) were recorded at baseline and at 1 and 3 months after the first intravitreal injection of ranibizumab.

Results: In the C, the CNV-PED complex thickness was reduced by 31.7% and 36.1% at 1 and 3 months, respectively; these reductions were significantly greater than the 19.7% and 24.2% reductions in the C. BCVA improvement was significantly greater in the C than in the C after 3 months; the proportion of patients with functional response was also greater in the C than in the C (16/16 vs. 8/17).

Conclusion: Oral cFXST increases the efficacy of short-term ranibizumab treatment for exudative AMD.

Citing Articles

Analysis of the Molecular Mechanism of Xueshuantong in the Treatment of Wet Age-Related Macular Degeneration (AMD) Using GEO Datasets, Network Pharmacology, and Molecular Docking.

Wang L, Wang C, Li L, Zhou X, Hua X, Yuan X Biochem Genet. 2024; 62(6):5004-5021.

PMID: 38383835 DOI: 10.1007/s10528-023-10654-9.

An Analysis of the Usage of Retinal Imaging Technology in the Detection of Age-Related Macular Degeneration.

Riazi Esfahani P, Reddy A, Thomas J, Sommer D, Nguyen A, Farasat V Cureus. 2023; 15(6):e40527.

PMID: 37461783 PMC: 10350318. DOI: 10.7759/cureus.40527.

Therapeutic effects of herbal medicines in different types of retinopathies: A systematic review.

Ansari-Mohseni N, Ghorani-Azam A, Mohajeri S Avicenna J Phytomed. 2023; 13(2):118-142.

PMID: 37333471 PMC: 10274316. DOI: 10.22038/AJP.2022.62423.2977.

Clinical Effect of Tongmai Fuming Decoction on Neovascular Ophthalmopathy.

Yang L, Zhou F, Xu Q, Ye T, Xiong H Evid Based Complement Alternat Med. 2022; 2022:7327609.

PMID: 36034947 PMC: 9410785. DOI: 10.1155/2022/7327609.

Clinical Efficacy of Xueshuantong plus Urokinase in the Treatment of Sudden Deafness.

Wang Y, Wang J, Chen X Evid Based Complement Alternat Med. 2022; 2022:7775556.

PMID: 35815266 PMC: 9259216. DOI: 10.1155/2022/7775556.

References

Michalska-Malecka K, Slowinska L, Dorecka M, Romaniuk W . Correlations in some pathogenetic factors and values of hemorheological parameters in age-related macular degeneration. Clin Hemorheol Microcirc. 2008; 38(3):209-16. View

Jian W, Yu S, Tang M, Duan H, Huang J . A combination of the main constituents of Fufang Xueshuantong Capsules shows protective effects against streptozotocin-induced retinal lesions in rats. J Ethnopharmacol. 2015; 182:50-6. DOI: 10.1016/j.jep.2015.11.021. View

Sridhar J, Hsu J, Shahlaee A, Garg S, Spirn M, Fineman M . Topical Dorzolamide-Timolol With Intravitreous Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2016; 134(4):437-43. DOI: 10.1001/jamaophthalmol.2016.0045. View

Spaide R, Guyer D, McCormick B, Yannuzzi L, Burke K, Mendelsohn M . External beam radiation therapy for choroidal neovascularization. Ophthalmology. 1998; 105(1):24-30. DOI: 10.1016/s0161-6420(98)90980-0. View

Krebs I, Glittenberg C, Ansari-Shahrezaei S, Hagen S, Steiner I, Binder S . Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol. 2013; 97(11):1443-6. DOI: 10.1136/bjophthalmol-2013-303513. View

Sheng S, Wang J, Wang L, Liu H, Li P, Liu M . Network pharmacology analyses of the antithrombotic pharmacological mechanism of Fufang Xueshuantong Capsule with experimental support using disseminated intravascular coagulation rats. J Ethnopharmacol. 2014; 154(3):735-44. DOI: 10.1016/j.jep.2014.04.048. View

Orlin A, Hadley D, Chang W, Ho A, Brown G, Kaiser R . Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina. 2011; 32(1):4-9. PMC: 7440363. DOI: 10.1097/IAE.0b013e31822a2c7c. View

Duan H, Huang J, Li W, Tang M . Protective effects of fufang xueshuantong on diabetic retinopathy in rats. Evid Based Complement Alternat Med. 2013; 2013:408268. PMC: 3800603. DOI: 10.1155/2013/408268. View

Bressler N, Bressler S, Hawkins B, Marsh M, Sternberg Jr P, Thomas M . Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. Ophthalmic outcomes submacular surgery trials pilot study report.... Am J Ophthalmol. 2000; 130(4):387-407. DOI: 10.1016/s0002-9394(00)00729-7. View

10.

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

11.

Liu H, Liang J, Li P, Peng W, Peng Y, Zhang G . Core bioactive components promoting blood circulation in the traditional Chinese medicine compound xueshuantong capsule (CXC) based on the relevance analysis between chemical HPLC fingerprint and in vivo biological effects. PLoS One. 2014; 9(11):e112675. PMC: 4232446. DOI: 10.1371/journal.pone.0112675. View

12.

Arnold J, Algan M, Soubrane G, Coscas G, Barreau E . Indirect scatter laser photocoagulation to subfoveal choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 1997; 235(4):208-16. DOI: 10.1007/BF00941761. View

13.

Martin D, Maguire M, Fine S, Ying G, Jaffe G, Grunwald J . Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012; 119(7):1388-98. PMC: 3389193. DOI: 10.1016/j.ophtha.2012.03.053. View

14.

Yi Z, Chen C, Su Y, Li L, Zhou Y . Changes in Clotting Time, Plasma Fibrinogen Levels, and Blood Viscosity After Administration of Ranibizumab for Treatment of Choroidal Neovascularization. Curr Eye Res. 2014; 40(11):1166-71. DOI: 10.3109/02713683.2014.990638. View

15.

Shin H, Chung H, Kim H . Correlation of foveal microstructural changes with vision after anti-vascular endothelial growth factor therapy in age-related macular degeneration. Retina. 2013; 33(5):964-70. DOI: 10.1097/IAE.0b013e3182835f70. View

16.

Brantley Jr M, Fang A, King J, Tewari A, Kymes S, Shiels A . Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007; 114(12):2168-73. DOI: 10.1016/j.ophtha.2007.09.008. View

17.

Lazic R, Gabric N . Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2007; 114(6):1179-85. DOI: 10.1016/j.ophtha.2007.03.006. View

18.

Lim L, Mitchell P, Seddon J, Holz F, Wong T . Age-related macular degeneration. Lancet. 2012; 379(9827):1728-38. DOI: 10.1016/S0140-6736(12)60282-7. View

19.

Ersoy L, Ristau T, Kirchhof B, Liakopoulos S . Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2013; 252(6):889-97. DOI: 10.1007/s00417-013-2519-9. View

20.

Heier J, Brown D, Chong V, Korobelnik J, Kaiser P, Nguyen Q . Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012; 119(12):2537-48. DOI: 10.1016/j.ophtha.2012.09.006. View